RenovaCare, Inc. (OTCMKTS:RCAR) Files An 8-K Other EventsItem 8.01Other Events.
On October 19, 2017, the Company closed its previously announced registered direct offering of an aggregate of 920,000 shares (the “Shares”) of the Company’s common stock, par value $0.00001 per share (the “Common Stock”). The Company sold the Shares at a price of $2.50 per share. The Company received gross proceeds from the offering of approximately $2.3 million, before estimated offering expenses payable by the Company. The offering was conducted directly by the Company without the assistance of any placement agents.
On October 19, 2017, the Company also closed its previously announced concurrent private placement for no additional consideration, of warrants (the “Warrants”) to purchase 920,000 shares of Common Stock. The Warrants are exercisable immediately on the date of issuance (the “Initial Exercise Date”), at an exercise price of $2.75 per share and will expire on the fifth (5th) anniversary of the Initial Exercise Date.
A copy of the press release announcing the closing of the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Exhibit 99.1 contains forward-looking statements regarding the Company, and includes cautionary statements identifying important factors that could cause actual results to differ materially from those anticipated.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press Release, dated October 20, 2017 |
RenovaCare, Inc. ExhibitEX-99.1 2 rcar_ex991.htm PRESS RELEASE rcar_ex991.htmEXHIBIT 99.1 Renovacare,…To view the full exhibit click here
About RenovaCare, Inc. (OTCMKTS:RCAR)
RenovaCare, Inc., formerly Janus Resources, Inc., is a biotechnology company. The Company is focused on the acquisition, research, development and commercialization of autologous cellular therapies that can be used for medical and aesthetic applications. The Company’s initial products under development target skin. The Company, through RenovaCare Sciences Corp., offers treatment methodology for cell isolation for the regeneration of human skin cells, along with a medical-grade liquid spraying device and associated equipment (the SkinGun). It is evaluating the efficacy and potential of SkinGun, in combination with a cell isolation method, in the treatment of tissue that has been subject to severe trauma. Its technology, the CellMist System, uses SkinGun to spray a liquid suspension of a patient’s stem cells, the CellMist Solution, onto wounds. The CellMist System harvests a patient’s stem cells from a small area of skin and suspends them in the water-based CellMist Solution.
